SHC
Sotera Health Company
SHC's fundamentals are strong and it looks cheap: trading at 27x earnings, less than half its usual 61x. Analysts expect earnings growth.
SHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Weak |
SHC's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is weak.
SHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $16.30 | — |
| Current | 27x | $16.30 | — |
| Cheap | 38x | $23.00 | +41% |
| Fair | 61x | $36.40 | +123% |
| Expensive | 173x | $104 | +538% |
Historical ranges are pointers, not guarantees.
SHC's PE is in its cheap range at 27x. If earnings grow as analysts expect, today's price would be 16x next year's earnings.
SHC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for SHC, with profitability improving.
SHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.04 | +73% |
| Q3 2026 | $0.60 | +200% |
| Q2 2026 | $0.57 | +533% |
| Q1 2026 | $0.41 | +356% |
| Q4 2025 | $0.27 | +69% |
| Q3 2025 | $0.20 | -20% |
| Q2 2025 | $0.09 | -36% |
| Q1 2025 | $0.09 | -53% |
| Q4 2024 | $0.16 | -11% |
SHC earned $0.60 per share over the past year, about three times what it earned the year before.
SHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $324.9M | +4.4% |
| Q2 2026 | $321.4M | +9.2% |
| Q1 2026 | $280M | +10% |
| Q4 2025 | $303.4M | +4.6% |
| Q3 2025 | $311.3M | +9.1% |
| Q2 2025 | $294.3M | +6.4% |
| Q1 2025 | $254.5M | +2.6% |
| Q4 2024 | $290.2M | -6.5% |
SHC's revenue has grown year over year for seven quarters in a row: $325M last quarter, up 4.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 26% | +2.3 points |
| Q2 2026 | 24% | +18 points |
| Q1 2026 | 15% | +21 points |
| Q4 2025 | 23% | -6.8 points |
| Q3 2025 | 23% | -4.8 points |
| Q2 2025 | 6.4% | -21 points |
| Q1 2025 | -5.8% | -27 points |
| Q4 2024 | 30% | -3.5 points |
SHC's operating margin was 26% last quarter, up 2.3 points from the same quarter a year ago.
SHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $57.7M | +65% |
| Q2 2026 | $42M | +61% |
| Q1 2026 | -$16.7M | -147% |
| Q4 2025 | $52.4M | +$62.6M |
| Q3 2025 | $35M | -43% |
| Q2 2025 | $26.2M | +35% |
| Q1 2025 | $35.6M | +$60.8M |
| Q4 2024 | -$10.2M | -121% |
SHC generated $135M in free cash flow over the past year, up 56% from the year before.
SHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +0.9% | +2.5M shares |
| 3 years | +2.9% | +8.1M shares |
| 5 years | +3.5% | +9.7M shares |
| Available history | +3.7% | +10.4M shares |
SHC has 289M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
SHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.3x | High |
| Q2 2026 | 4.6x | High |
| Q1 2026 | 5.5x | High |
| Q4 2025 | 6.3x | High |
| Q3 2025 | 6.0x | High |
| Q2 2025 | 5.7x | High |
| Q1 2025 | 4.9x | High |
| Q4 2024 | 4.2x | High |
SHC's net debt is about 4.3 years of its operating earnings (EBITDA), down from 6.0 years a year ago.
SHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.0 | Neutral |
| Stochastic | 20.9 | Neutral |
SHC's weekly RSI is 41 (neutral) and its Stochastic is 21 (neutral).
SHC PE vs Healthcare Sector
| Metric | SHC | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 26x | 5.1% above |
| PE % | 8 | 34 | 26 pts below |
SHC is trading at 27x earnings, in line with the Healthcare sector's median of 26x.
SHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.6 | 7.5% below |
| 20 week MA | $18.2 | 10% below |
| 50 week MA | $17.1 | 4.4% below |
| 100 week MA | $15.3 | 6.7% above |
| 200 week MA | $15.1 | 7.9% above |
SHC has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 7.9% above its 200-week average.
SHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.1 | $26.9 | +7.3% |
| 2021 | $26.9 | $23.6 | -13% |
| 2022 | $23.6 | $7.93 | -66% |
| 2023 | $7.93 | $16.9 | +112% |
| 2024 | $16.9 | $13.5 | -20% |
| 2025 | $13.5 | $17.7 | +31% |
| 2026 YTD | $17.7 | $16.3 | -7.9% |
SHC's yearly returns have swung widely, from +112% in 2023 to −66% in 2022. It's down 7.9% so far in 2026.